Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

18.78 +1.05 (+5.92%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novocure Ltd Ord Sh

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
NovoCure (NVCR) Q3 2024 Earnings Call Transcript
NVCR earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips
U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why NovoCure Stock Dived by 13% This Week
Investors found the announced changes to the company's C-suite unsettling. 
Via The Motley Fool
Beyond The Numbers: 4 Analysts Discuss NovoCure Stock
Via Benzinga
Breaking Down NovoCure: 4 Analysts Share Their Views
Via Benzinga
A Closer Look at 7 Analyst Recommendations For NovoCure
Via Benzinga
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non-small cell lung cancer patients, demonstrating significant... 
Via Benzinga
Exposures Product Safety
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
The company could have a long path ahead to reimbursement and, ultimately, sales. 
Via Investor's Business Daily
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Chips, Glorious Chips!
Someone's gotta make 'em, and someone's gotta buy 'em. 
Via The Motley Fool
PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
NovoCure (NVCR) Q2 2024 Earnings Call Transcript
NVCR earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q2 2024
NVCR stock results show that NovoCure beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Unveiling 8 Analyst Insights On NovoCure
Via Benzinga
Why NovoCure Stock Soared 18.3% This Week
Novocure announced encouraging results in a phase 3 trial for its TTFields therapy. 
Via The Motley Fool
Why Novocure Stock Is Jumping Today
Novocure had good news mixed with some not-so-good news. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet. 
Via InvestorPlace
Peeling Back The Layers: Exploring NovoCure Through Analyst Insights
Via Benzinga
NovoCure (NVCR) Q1 2024 Earnings Call Transcript
NVCR earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024
NVCR stock results show that NovoCure beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows
Novocure's Phase 3 METIS trial results: TTFields therapy, combined with supportive care, significantly prolongs time to intracranial progression for NSCLC brain metastases patients compared to... 
Via Benzinga
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment
The company uses electrical fields to interrupt the rampant cellular division characteristic of cancer. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.